title: The Crusade against Mutant p53: Does the COMPASS Point to the Holy Grail?
abstract: Mutations in the TP53 gene not only inactivate its tumor suppressor function but also confer this transcription factor with gain-of-function oncogenic properties. A recent paper by Zhu and colleagues reveals a novel molecular pathway driven by mutant p53 and the COMPASS chromatin-modifying complex that is amenable to pharmacological inhibition.
authors.affiliation: Linda Crnic Institute for Down Syndrome, University of Colorado Denver School Of Medicine, Aurora, CO 80045, USA; Department of Pharmacology, University of Colorado Denver School Of Medicine, Aurora, CO 80045, USA.
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Abraham
authors.affiliation: Linda Crnic Institute for Down Syndrome, University of Colorado Denver School Of Medicine, Aurora, CO 80045, USA; Department of Pharmacology, University of Colorado Denver School Of Medicine, Aurora, CO 80045, USA. Electronic address: joaquin.espinosa@ucdenver.edu.
authors.forename: Joaquín M
authors.initials: JM
authors.lastname: Espinosa
mesh_terms: D000818:Animals; D002843:Chromatin / Q000235:genetics* / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D009154:Mutation / Q000235:genetics*; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism*
chemical_list: D002843:Chromatin; D016159:Tumor Suppressor Protein p53